Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:ELVNNASDAQ:NAGENASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$7.48-11.7%$8.10$5.20▼$10.67$1.14B1.161.36 million shs3.31 million shsELVNEnliven Therapeutics$19.65-2.0%$19.43$13.30▼$30.03$984.33M0.83293,183 shs884,482 shsNAGENiagen Bioscience$12.81-11.1%$11.08$2.40▼$14.69$1.14B2.14939,751 shs1.76 million shsTRDAEntrada Therapeutics$7.11+5.8%$7.98$6.53▼$21.79$255.05M-0.11134,114 shs205,752 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals-1.97%+8.17%+7.76%+5.22%+48.34%ELVNEnliven Therapeutics-3.00%-1.13%+12.44%+6.25%-14.16%NAGENiagen Bioscience+1.34%+5.65%+33.30%+109.75%+427.84%TRDAEntrada Therapeutics-2.75%-4.55%-12.27%-23.29%-52.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals3.4006 of 5 stars3.51.00.00.02.60.83.1ELVNEnliven Therapeutics2.2852 of 5 stars3.50.00.00.02.64.20.0NAGENiagen Bioscience1.4895 of 5 stars3.50.00.00.02.50.00.0TRDAEntrada Therapeutics3.3874 of 5 stars3.62.00.00.02.02.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5053.74% UpsideELVNEnliven Therapeutics 3.00Buy$39.60101.53% UpsideNAGENiagen Bioscience 3.00Buy$19.5052.22% UpsideTRDAEntrada Therapeutics 3.25Buy$25.67260.99% UpsideCurrent Analyst Ratings BreakdownLatest TRDA, NAGE, AUPH, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.006/10/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.006/6/2025NAGENiagen BioscienceRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $23.005/27/2025NAGENiagen BioscienceCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.005/20/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M4.30$0.27 per share27.46$2.68 per share2.79ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/ANAGENiagen Bioscience$99.60M10.13$0.05 per share243.62$0.60 per share21.35TRDAEntrada Therapeutics$210.78M1.28$1.68 per share4.23$11.46 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.2826.7113.36N/A16.11%14.27%9.93%7/30/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)NAGENiagen Bioscience$8.55M$0.1775.35∞N/A13.07%19.06%12.20%N/ATRDAEntrada Therapeutics$65.63M$0.818.78N/AN/A14.39%5.84%4.61%8/12/2025 (Estimated)Latest TRDA, NAGE, AUPH, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q1 2025TRDAEntrada Therapeutics-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.165.935.26ELVNEnliven TherapeuticsN/A21.0721.06NAGENiagen BioscienceN/A3.663.12TRDAEntrada TherapeuticsN/A21.8821.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%ELVNEnliven Therapeutics95.08%NAGENiagen Bioscience15.41%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%ELVNEnliven Therapeutics25.90%NAGENiagen Bioscience9.39%TRDAEntrada Therapeutics7.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableNAGENiagen Bioscience12078.77 million71.37 millionN/ATRDAEntrada Therapeutics11037.95 million35.07 millionOptionableTRDA, NAGE, AUPH, and ELVN HeadlinesRecent News About These CompaniesInsider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,422 Shares of Stock2 hours ago | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 18,578 Shares2 hours ago | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 19,265 Shares2 hours ago | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 25,000 Shares2 hours ago | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 55,735 Shares2 hours ago | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street ZenJune 29 at 2:07 AM | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Upgraded to "Hold" at Wall Street ZenJune 27, 2025 | marketbeat.comWall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to SellJune 14, 2025 | marketbeat.comMillennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)June 12, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLCJune 4, 2025 | marketbeat.comEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29, 2025 | morningstar.comMEntrada Therapeutics to start DMD trial in Q3 2025May 29, 2025 | investing.comEntrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025May 29, 2025 | nasdaq.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMay 28, 2025 | globenewswire.comAnalysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest ResultsMay 11, 2025 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comEntrada Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comEntrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other CandidatesMay 2, 2025 | precisionmedicineonline.comPEntrada Cuts 20% of Workforce, Targeting Research EmployeesApril 30, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideBy Gabriel Osorio-Mazilli | June 25, 2025View ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernAnalysts Are All In on This Tech Stock—Why You Should Be, TooBy Nathan Reiff | July 1, 2025View Analysts Are All In on This Tech Stock—Why You Should Be, TooTRDA, NAGE, AUPH, and ELVN Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$7.48 -0.99 (-11.69%) Closing price 04:00 PM EasternExtended Trading$7.66 +0.18 (+2.41%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Enliven Therapeutics NASDAQ:ELVN$19.65 -0.41 (-2.04%) Closing price 04:00 PM EasternExtended Trading$19.65 0.00 (0.00%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Niagen Bioscience NASDAQ:NAGE$12.81 -1.60 (-11.10%) As of 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Entrada Therapeutics NASDAQ:TRDA$7.11 +0.39 (+5.80%) Closing price 04:00 PM EasternExtended Trading$7.10 -0.01 (-0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
